MVCD3
MCID: MCR113
MIFTS: 52

Microvascular Complications of Diabetes 3 (MVCD3)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 3

MalaCards integrated aliases for Microvascular Complications of Diabetes 3:

Name: Microvascular Complications of Diabetes 3 56 73 29 13 6 37
Diabetic Nephropathy 74 73 36 17 71
Mvcd3 56 73
Microvascular Complications of Diabetes, Susceptibility to, 3 56
End-Stage Renal Disease, Diabetic, Susceptibility to 56
Nephropathy, Diabetic, Susceptibility to 56
End-Stage Renal Disease, Diabetic 56
Diabetic End-Stage Renal Disease 73
Diabetic Nephropathies 54
Nephropathy, Diabetic 56

Classifications:



External Ids:

OMIM 56 612624
OMIM Phenotypic Series 56 PS603933
KEGG 36 H01456
MeSH 43 D048909
UMLS 71 C0011881

Summaries for Microvascular Complications of Diabetes 3

KEGG : 36 Diabetic nephropathy (DN), also called diabetic kidney disease, is a microvascular complication of diabetes which induces dysfunction in various cell types of the kidney, ultimately leading to the renal failure. A clinical syndrome of DN is characterized by decreased Glomerular Filteration Rate (GFR), excessive deposition of extracellular matrix proteins, thickening of the peripheral glomerular basement membrane, glomerular hypertrophy, tubulointerstitial fibrosis, increased excretion of albumin and decreased creatinine clearance. Generally, DN is divided into five stages: (i) hyperfunction with raised GFR and increased kidney volume; (ii) normalbuminuria with the thickening of the glomerular basement membrane (GBM) and the expansion of the mesangial matrix; (iii) incipient DN with MAU (30-299 mg per day); (iv) overt DN with macroalbuminuria (>300 mg per day); (v) uremia with end-stage renal disease. It has been reported that angiotensin-vonverting enzyme, vascular endothelial growth factor A and superoxide dismutase 2 are associated with DN.

MalaCards based summary : Microvascular Complications of Diabetes 3, also known as diabetic nephropathy, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 5. An important gene associated with Microvascular Complications of Diabetes 3 is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and Renin-angiotensin system. The drugs Pioglitazone and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include Kidney, endothelial and pancreas, and related phenotype is renal/urinary system.

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 3: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

Wikipedia : 74 Diabetic nephropathy(DN), also known as diabetic kidney disease, is the chronic loss of kidney function... more...

More information from OMIM: 612624 PS603933

Related Diseases for Microvascular Complications of Diabetes 3

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.6 INS CCN2 AKR1B1
2 microvascular complications of diabetes 5 31.6 MIR21 INS CCN2 ALB AKR1B1 AGTR1
3 iga glomerulonephritis 30.9 NPHS1 ALB AGTR1 ACE
4 autonomic neuropathy 30.8 INS ALB AKR1B1
5 diabetic neuropathy 30.7 INS AKR1B1 ACE
6 interstitial nephritis 30.6 ALB AGTR1 ACE
7 acute cystitis 30.6 INS ALB ACE
8 atherosclerosis susceptibility 30.6 INS ALB AGTR1 ACE
9 lipoprotein quantitative trait locus 30.5 MIR21 ALB AGTR1 ACE
10 iga nephropathy 1 30.5 NPHS1 AGTR1 ACE
11 cerebrovascular disease 30.5 MIR21 INS AGTR1 ACE
12 fatty liver disease 30.5 MIR21 MALAT1 INS ALB
13 congestive heart failure 30.5 INS ALB AGTR1 ACE
14 end stage renal disease 30.5 PVT1 NPHS1 INS ALB AGTR1 ACE
15 retinal microaneurysm 30.4 INS AKR1B1
16 polycystic kidney disease 30.4 MIR192 ALB AGTR1 ACE
17 kidney hypertrophy 30.4 NPHS1 INS CCN2 ALB ACE
18 arteries, anomalies of 30.4 MIR21 INS ALB AGTR1 ACE
19 pre-eclampsia 30.4 MALAT1 INS ALB AGTR1 ACE
20 glomerular disease 30.3 NPHS1 ALB ACE
21 sleep apnea 30.3 INS ALB ACE
22 uremia 30.3 INS ALB ACE
23 sexual disorder 30.2 INS ALB ACE
24 rapidly progressive glomerulonephritis 30.2 TGFB1 NPHS1 ALB
25 polyneuropathy 30.1 INS ALB AKR1B1 ACE
26 coronary stenosis 30.1 MIR21 ALB ACE
27 pyelonephritis 30.1 TGFB1 NAGLU ALB ACE
28 drug allergy 30.0 INS ALB ACE
29 maturity-onset diabetes of the young, type 1 30.0 INS ALB ACE
30 macular retinal edema 30.0 INS ALB AKR1B1 ACE
31 hypertensive retinopathy 30.0 ALB AGTR1 ACE
32 apnea, obstructive sleep 30.0 INS ALB ACE
33 cardiovascular system disease 30.0 MIR217 MIR21 INS ALB AGTR1 ACE
34 mineral metabolism disease 30.0 INS ALB ACE
35 obstructive nephropathy 30.0 TGFB1 ALB ACE
36 focal segmental glomerulosclerosis 30.0 TGFB1 NPHS1 ALB AGTR1 ACE
37 impotence 29.9 INS ALB ACE
38 diabetic autonomic neuropathy 29.9 INS AKR1B1 ACE
39 background diabetic retinopathy 29.9 INS ALB AKR1B1 ACE
40 acute kidney tubular necrosis 29.9 NAGLU ALB ACE
41 idiopathic nephrotic syndrome 29.9 TGFB1 ALB ACE
42 hyperglycemia 29.8 NPHS1 MALAT1 INS ALB AKR1B1 AGTR1
43 nephrosclerosis 29.8 TGFB1 NPHS1 INS CCN2 AGTR1 ACE
44 non-alcoholic fatty liver disease 29.8 TGFB1 MIR21 MIR192 INS ALB
45 lipoid nephrosis 29.7 NPHS1 NAGLU ALB
46 renal hypertension 29.7 NPHS1 ALB AGTR1 ACE
47 severe nonproliferative diabetic retinopathy 29.7 INS ALB AKR1B1 ACE
48 liver cirrhosis 29.7 TGFB1 MALAT1 CCN2 ALB
49 membranous nephropathy 29.6 NPHS1 ALB AKR1B1 ACE
50 hypertensive nephropathy 29.6 NAGLU ALB AGTR1 ACE

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 3:



Diseases related to Microvascular Complications of Diabetes 3

Symptoms & Phenotypes for Microvascular Complications of Diabetes 3

Clinical features from OMIM:

612624

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 3:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.23 ACE AGTR1 AKR1B1 ALB INS NAGLU

Drugs & Therapeutics for Microvascular Complications of Diabetes 3

Drugs for Microvascular Complications of Diabetes 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
4
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
5
Nifedipine Approved Phase 4 21829-25-4 4485
6
Fenofibrate Approved Phase 4 49562-28-9 3339
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Methyldopa Approved Phase 4 555-30-6 38853
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
13
Nisoldipine Approved Phase 4 63675-72-9 4499
14
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
15
Probucol Approved, Investigational Phase 4 23288-49-5 4912
16
Doxazosin Approved Phase 4 74191-85-8 3157
17
Atorvastatin Approved Phase 4 134523-00-5 60823
18
Indapamide Approved Phase 4 26807-65-8 3702
19
Nitric Oxide Approved Phase 4 10102-43-9 145068
20
Insulin glulisine Approved Phase 4 207748-29-6
21
Insulin glargine Approved Phase 4 160337-95-1
22
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
23
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
24
Insulin lispro Approved Phase 4 133107-64-9
25
Ramipril Approved Phase 4 87333-19-5 5362129
26
Liraglutide Approved Phase 4 204656-20-2 44147092
27
Glucagon Approved Phase 4 16941-32-5
28
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
29
Amlodipine Approved Phase 4 88150-42-9 2162
30
Clonidine Approved Phase 4 4205-90-7 2803
31
Atenolol Approved Phase 4 29122-68-7 2249
32
Trandolapril Approved Phase 4 87679-37-6 5484727
33
Verapamil Approved Phase 4 52-53-9 2520
34
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
35
Lixisenatide Approved Phase 4 320367-13-3
36
Glimepiride Approved Phase 4 93479-97-1 3476
37
Hydralazine Approved Phase 4 86-54-4 3637
38
Terazosin Approved Phase 4 63590-64-7 5401
39
Febuxostat Approved Phase 4 144060-53-7 134018
40
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
41
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
42
Canagliflozin Approved Phase 4 842133-18-0
43
Histamine Approved, Investigational Phase 4 51-45-6 774
44
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
45
Gliclazide Approved Phase 4 21187-98-4 3475
46
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
47
Niclosamide Approved, Investigational, Vet_approved Phase 4 50-65-7 4477
48
Adenosine Approved, Investigational Phase 4 58-61-7 60961
49
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
50
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807

Interventional clinical trials:

(show top 50) (show all 491)
# Name Status NCT ID Phase Drugs
1 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
2 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
5 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
6 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
7 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
8 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
9 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
10 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
11 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
12 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
13 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
14 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
15 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
16 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
17 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
18 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
19 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
20 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
21 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
22 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
23 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
24 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
25 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
26 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
27 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
28 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
29 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
30 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
31 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
32 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
33 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
34 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
35 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
36 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
37 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
38 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study Completed NCT00153023 Phase 4 Telmisartan;Valsartan
39 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
40 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
41 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
42 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
43 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
44 Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes Completed NCT02914691 Phase 4 Dapagliflozine 10 mg once daily tablet treatment;Placebo identical once daily tablet treatment
45 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
46 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
47 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
48 Comparative Effects of add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on Serum NT-PRO BNP and Proteinuria in Type 2 Diabetics With Nephropathy Completed NCT03006952 Phase 4 Pentoxifylline;Losartan
49 Effect of Glucose in Dialysis Water in Diabetics With Chronic Renal Failure on Blood Pressure, Pulse Rate, Plasma Glucose, Plasma Concentrations of Insulin, Growth Hormone, Renin, Angiotensin II, Endothelin and Body Temperature Completed NCT00438503 Phase 4
50 Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial Completed NCT02545738 Phase 4 Liraglutide;placebo

Search NIH Clinical Center for Microvascular Complications of Diabetes 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Microvascular Complications of Diabetes 3:
Mesenchymal precursor cells for type 2 diabetes
Embryonic/Adult Cultured Cells Related to Microvascular Complications of Diabetes 3:
Mesenchymal Precursor Cells (STRO-3 selected)

Genetic Tests for Microvascular Complications of Diabetes 3

Genetic tests related to Microvascular Complications of Diabetes 3:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 3 29 ACE

Anatomical Context for Microvascular Complications of Diabetes 3

MalaCards organs/tissues related to Microvascular Complications of Diabetes 3:

40
Kidney, Endothelial, Pancreas, Heart, Bone, Liver, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 3:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Podocyte Layer Podocytes Affected by disease, potential therapeutic candidate

Publications for Microvascular Complications of Diabetes 3

Articles related to Microvascular Complications of Diabetes 3:

(show top 50) (show all 18157)
# Title Authors PMID Year
1
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. 56 54 6 61
7729604 1995
2
Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. 61 54 6 56
8314010 1994
3
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 61 56 6
11687636 2001
4
The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. 61 6 56
10099885 1999
5
Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. 56 6 61
9120002 1997
6
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. 56 6 61
7909524 1994
7
Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. 56 54 61
7783416 1995
8
Review: The role of microRNAs in kidney disease. 61 46
20883280 2010
9
Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. 61 46
20056746 2010
10
MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. 46 61
19450585 2009
11
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 6
19221299 2009
12
MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. 61 46
18716028 2008
13
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 6
15635071 2005
14
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 6
15531537 2004
15
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 6
15534175 2004
16
ACE1 polymorphism and progression of SARS. 6
15381116 2004
17
Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. 56
15164285 2004
18
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 6
15277638 2004
19
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 6
15110771 2004
20
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 6
14872014 2004
21
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 6
14657821 2003
22
Phenotype modulators in myophosphorylase deficiency. 6
12666117 2003
23
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 6
12220450 2002
24
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 6
11956052 2002
25
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. 6
10841123 2000
26
Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. 6
10643899 1999
27
A dominant relationship between the ACE D allele and serum ACE levels in a Ghanaian population. 6
10636736 1999
28
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. 6
9916793 1999
29
ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. 6
9699903 1998
30
Elite endurance athletes and the ACE I allele--the role of genes in athletic performance. 6
9737775 1998
31
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 6
9259580 1997
32
D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. 6
9236417 1997
33
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. 6
8644984 1996
34
Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. 6
8675669 1995
35
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 6
8541160 1995
36
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. 6
7593601 1995
37
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. 6
7854377 1995
38
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. 6
8208911 1994
39
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 6
8170965 1994
40
Genetic associations with human longevity at the APOE and ACE loci. 6
8136829 1994
41
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. 6
8131299 1993
42
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. 6
8131300 1993
43
A potent genetic risk factor for restenosis. 6
8298638 1993
44
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. 6
1328889 1992
45
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. 6
1386652 1992
46
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. 6
1319114 1992
47
PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). 6
1313972 1992
48
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. 6
1976655 1990
49
Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. 6
2849100 1988
50
Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. 6
2847529 1988

Variations for Microvascular Complications of Diabetes 3

ClinVar genetic disease variations for Microvascular Complications of Diabetes 3:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ACE NM_000789.3(ACE):c.2306-117_2306-116insAF118569.1:g.14094_14382insertion risk factor 18061 17:61565892-61565893 17:63488531-63488532

Expression for Microvascular Complications of Diabetes 3

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 3.

Pathways for Microvascular Complications of Diabetes 3

Pathways related to Microvascular Complications of Diabetes 3 according to KEGG:

36
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933
2 Renin-angiotensin system hsa04614
3 FoxO signaling pathway hsa04068
4 Longevity regulating pathway hsa04211

Pathways related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.7 TGFB1 AGTR1 ACE

GO Terms for Microvascular Complications of Diabetes 3

Cellular components related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 TGFB1 MIR21 MIR192 INS CCN2 ALB

Biological processes related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.8 MIR377 MIR217 MIR216A MIR21 MIR192
2 negative regulation of gene expression GO:0010629 9.73 TGFB1 MIR21 CCN2 ACE
3 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.46 MIR21 INS
4 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.37 AGTR1 ACE
5 connective tissue development GO:0061448 9.32 TGFB1 CCN2
6 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.26 MIR21 MIR192
7 negative regulation of interleukin-21 production GO:0032705 9.16 MIR21 MIR192
8 mononuclear cell proliferation GO:0032943 8.96 TGFB1 ACE
9 positive regulation of cellular protein metabolic process GO:0032270 8.8 TGFB1 INS AGTR1

Molecular functions related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Microvascular Complications of Diabetes 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....